Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616728 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
A Phase 2 study of COVID-19, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT05616728 is a Phase 2 study of COVID-19 that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 231 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05616728, a Phase 2 study of COVID-19, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-235
Study Locations (20)
Florida
- MedBio Trials - Miami - Aventura
- Doral Medical Research - Doral
- Encore Medical Research - Hollywood - Hollywood
- Universal Medical and Research Center, LLC - Hollywood
- Advanced Research for Health Improvement, LLC - Immokalee
- LCC Medical Research - Miami - ClinEdge - PPDS - Miami
- USPA Advance Concept Medical Research Group. LLC - Miami
- Continental Clinical Research, LLC - Miami
- Dynamic Medical Research, LLC - Miami - Miami
- BioClinical Research Alliance - Miami
- D&H National Research Centers - Miami
- Florida International Medical Research - Miami
- C'A Medical Center Inc Research - Miami
- Reed Medical Research - Miami
- CDC Research Institute, LLC - Port Saint Lucie
California
- Torrance Clinical Research Institute - Lomita
- LA Universal Research Center, Inc. - Los Angeles
North Carolina
- Carolina Research Center - Shelby
Ohio
- Toledo Institute of Clinical Research - Toledo
Texas
- Trio Clinical Trials LLC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05616728
The ClinicalTrials.gov registry entry for NCT05616728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05616728 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05616728 about?
NCT05616728 is a clinical study titled "A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19". Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
What is the current status of trial NCT05616728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2022-11-10. Estimated completion is 2023-06-29.
What conditions does trial NCT05616728 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05616728?
The interventions under investigation include: Placebo (DRUG), EDP-235 (DRUG).
Who is sponsoring clinical trial NCT05616728?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05616728 being conducted?
This trial has 20 study locations across California, Florida, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.